Introduction
CRITICALLY ILL, SARS-COV-2 INFECTION, INFLAMMATORY DISORDER, SEPTIC SHOCK, MACROPHAGE ACTIVATION SYNDROME
COVID-19 has resulted in millions of cases worldwide. Multiple variants of SARS-CoV-2 have emerged that vary in terms of transmissibility and severity. The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for the Omicron variant than for the Delta variant. Although more than 80% of patients experience mild symptoms, a substantial proportion can be critically ill, especially those who are older and those with comorbidities.Anakinra is a recombinant IL-1 receptor antagonist that has traditionally been used in scenarios with features similar to those of COVID-19 hyperinflammation, including macrophage activation syndrome caused by severe inflammatory disorders and septic shock.